OUTCOME OF ULCERATIVE COLITIS PATIENTS AFTER ONE YEAR OF BIOLOGICAL THERAPY IN SELECTED EGYPTIAN PATIENTS | ||||
| Journal of the Egyptian Society of Parasitology | ||||
| Volume 52, Issue 2, August 2022, Page 279-286 PDF (785.71 K) | ||||
| DOI: 10.21608/jesp.2022.257456 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
| SAFAA R. ASKAR1; ASHRAF AMIN1; RADWA SAMIR HAGAG2; NADEEN ASHRAF1; YASMEEN AHMED1 | ||||
| 1Department of Tropical Medicine, Ain Shams University, Faculty of Medicine | ||||
| 2Department of Pharmacy Practice and Clinical Pharmacy, Egyptian Russian University, Cairo, Egypt | ||||
| Abstract | ||||
| The majority of inflammatory bowel disease (IBD) patients can live normal productive lives; but long-term ulcerative colitis is associated with a higher risk of dysplasia and colorectal cancer. Anti-TNF drugs remain the first-line therapy for moderate-to-severe IBD patients but these drugs have several drawbacks for the majority of patients. This study assessed one-year followup of ulcerative colitis patients receiving biological therapy. Selected twenty-eight patients with moderate to severe ulcerative colitis treated with biological therapy for at least one year were enrolled. Clinical and laboratory assessments were performed for patients before and after the biological treatment as well as assessments of clinical response and remission. The results showed that after one year, patients (75%) clinical responded and clinical remission was in 46.4% of them. There was a significant improvement in Mayo Score and Mayo Endoscopic Sub-score. | ||||
| Keywords | ||||
| Patients; Inflammatory bowel disease; Mayo Score; Clinical response; Remission | ||||
|
Statistics Article View: 143 PDF Download: 174 |
||||
